At a glance
- Originator sanofi-aventis
- Class
- Mechanism of Action Neurokinin 3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anxiety disorders; Major depressive disorder; Respiratory tract disorders; Schizophrenia
Most Recent Events
- 11 Feb 2009 Discontinued - Phase-I for Anxiety disorders (unspecified route)
- 11 Feb 2009 Discontinued - Phase-I for Depression (unspecified route)
- 11 Feb 2009 Discontinued - Phase-I for Schizophrenia (unspecified route)